Abstract
We conducted a prospective, multi-centre, open, randomized study in 11 UK hospitals to compare iv meropenem 1 g tds with the combination of iv cefotaxime 1 g tds and iv metronidazole 500 mg tds in patients with serious infections. One hundred and sixty-one patients were enrolled, of whom 131 were clinically evaluable (meropenem, n = 68; cefotaxime/metronidazole, n = 63). The most common infections were subsequent to intra-abdominal pathology (meropenem, n = 77%; cefotaxime/metronidazole, n = 75%), and were usually accompanied by septicaemia (meropenem, n = 61%; cefotaxime/metronidazole, n = 53%). The incidence of a satisfactory clinical response was similar in the two groups at the end of treatment (93% for meropenem; 92% for cefotaxime/metronidazole) and up to 8 weeks later (96% for meropenem; 93% for cefotaxime/metronidazole). Satisfactory bacteriological response (success or presumed success) was recorded at the end of therapy in 86% of meropenem and 88% of cefotaxime/metronidazole patients. Adverse events were reported in 32% of meropenem and 25% of cefotaxime/metronidazole patients, and most were mild or moderate and did not require discontinuation of therapy. Twenty-one patients (ten meropenem and 11 cefotaxime/metronidaz...Continue Reading
Citations
Aug 26, 1998·International Journal of Antimicrobial Agents·B A Cunha
Jan 25, 2003·Surgical Infections·John E MazuskiUNKNOWN Therapeutic Agents Committee of the Surgical Infections Society
Nov 16, 2004·Critical Care Medicine·Pierre-Yves BochudThierry Calandra
Dec 6, 2008·Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies·Philip ToltzisJeffrey Blumer
Apr 28, 2005·Antimicrobial Agents and Chemotherapy·Wolfgang A KruegerFritz Sörgel
Jul 6, 2012·Clinical Microbiology Reviews·Pranita D TammaLisa L Maragakis
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Joseph S SolomkinUNKNOWN Infectious Diseases Society of America
Apr 20, 2014·The Journal of Antimicrobial Chemotherapy·Joan P CannonShellee A Grim
Mar 13, 2008·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·P KujathA Rodloff
Dec 19, 2009·Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen·K-F Bodmann, UNKNOWN und die Expertenkommission der Infektliga
Jun 25, 1999·Scandinavian Journal of Infectious Diseases·S R Norrby, K M Gildon
Mar 29, 2011·Critical Care Clinics·Cybéle L AbadNasia Safdar
Mar 10, 2001·Journal of Chemotherapy·F Alvarez Lerma, UNKNOWN Serious Infection Study Group
Mar 18, 2000·Journal of Chemotherapy·D D'Amico, U Cillo
Oct 12, 2005·Archives of Medical Research·M Sigfrido Rangel-Frausto
Jan 30, 2007·Expert Opinion on Pharmacotherapy·Ioannis P KioumisDavid P Nicolau
Oct 22, 2008·Expert Opinion on Pharmacotherapy·Diogo Diniz Gomes BuganoEliezer Silva
Dec 3, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hiroshige MikamoMasahito Nagashima
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Apr 23, 2005·The Cochrane Database of Systematic Reviews·P F WongD J Leaper
Apr 18, 2008·Drugs·Claudine M BaldwinSusan J Keam
Dec 29, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xiuwen WuJianan Ren
Sep 16, 1998·Antimicrobial Agents and Chemotherapy·W A KruegerK Unertl